Nurfaradilla Shinta Ayu, Saputri Fadlina Chany, Harahap Yahdiana
Graduate Program, Faculty of Pharmacy, Universitas Indonesia, Kampus UI Depok 16424, Indonesia.
Laboratory of Pharmacology, Faculty of Pharmacy, Universitas Indonesia, Kampus UI Depok 16424, Indonesia.
Evid Based Complement Alternat Med. 2019 Jul 17;2019:9694212. doi: 10.1155/2019/9694212. eCollection 2019.
aqueous extract (HS) is often used as complementary therapy for hypertension. However, some studies have shown that coadministration with a conventional antihypertensive drug can affect drug potency. We compared the effects of HS plus captopril (CAP) coadministration to HS and CAP administration alone on blood pressure and renin-angiotensin-aldosterone system (RAAS) biomarkers in the rat two-kidney-one-clip (2K1C) model of hypertension. Male Sprague Dawley rats were randomly divided into seven groups (n=6/group), a normal control (SHAM) group, and six 2K1C groups. In 2K1C animals, hypertension was induced using a stainless microclip (inner diameter of 0.20 mm). Four weeks after 2K1C surgery, blood pressure was significantly higher than in the SHAM group. Then, model rats were randomly divided into negative control (2K1C, no treatment), positive control (4.5 mg captopril/200 g body weight [BW] orally [p.o.]), HS alone (30 mg/200 g BW; p.o.), and 3 co-treatment groups receiving HS (15, 30, or 60 mg/200 g BW; p.o.) plus 4.5 mg/200 g BW captopril. The treatments were performed for two weeks. Blood pressure was significantly reduced by all the drug treatments to near the level of SHAM controls. Plasma renin level, serum angiotensin converting enzyme (ACE) activity, and plasma angiotensin II level were also significantly elevated in the 2K1C group compared to the SHAM group. Both serum ACE activity and plasma angiotensin II level were significantly reduced to near SHAM group levels by all the drug treatments. aqueous extract alone can reduce blood pressure. This extract appears could be used as a supplement with captopril but may not provide any additional benefit.
水提取物（HS）常被用作高血压的辅助治疗方法。然而，一些研究表明，与传统抗高血压药物联合使用可能会影响药物效力。我们在大鼠双肾单夹（2K1C）高血压模型中，比较了HS加卡托普利（CAP）联合给药与单独给予HS和CAP对血压及肾素-血管紧张素-醛固酮系统（RAAS）生物标志物的影响。雄性Sprague Dawley大鼠随机分为七组（每组n = 6），即正常对照组（SHAM）和六个2K1C组。在2K1C动物中，使用内径为0.20 mm的不锈钢微夹诱导高血压。2K1C手术四周后，血压显著高于SHAM组。然后，将模型大鼠随机分为阴性对照组（2K1C，不治疗）、阳性对照组（口服4.5 mg卡托普利/200 g体重[p.o.]）、单独HS组（30 mg/200 g体重；p.o.）以及3个联合治疗组，分别接受HS（15、30或60 mg/200 g体重；p.o.）加4.5 mg/200 g体重卡托普利。治疗持续两周。所有药物治疗均使血压显著降低至接近SHAM对照组水平。与SHAM组相比，2K1C组的血浆肾素水平、血清血管紧张素转换酶（ACE）活性和血浆血管紧张素II水平也显著升高。所有药物治疗均使血清ACE活性和血浆血管紧张素II水平显著降低至接近SHAM组水平。单独的水提取物可降低血压。该提取物似乎可与卡托普利联合使用，但可能不会带来任何额外益处。
